Targeted drug administration, also known as smart drug delivery, is a technique for administering medications to a patient in such a way that the medication is more concentrated in some areas of the body than others. This method of delivery is mostly based on nanomedicine, which aims to use medication administration via nanoparticles to counter the drawbacks of traditional drug delivery. These drug-loaded nanoparticles would be directed to specific areas of the body that only contain sick tissue, avoiding contact with healthy tissue. A targeted medicine delivery system aims to extend, localise, target, and engage with the sick tissue in a safe manner. While the targeted release system delivers the medicine in a dose form, the traditional drug delivery method involves the drug being absorbed through a biological membrane. The patient will need to take fewer doses more frequently, the medicine will have a more consistent impact, there will be fewer adverse effects, and there will be less volatility in the drug levels in the blood. The system's drawbacks include a hefty price tag that makes productivity more challenging and a limited capacity to change doses. To maximise the effectiveness of regeneration methods, targeted medication delivery systems have been created. The system is based on a technique that delivers a specific quantity of a therapeutic drug to a particular sick location over an extended period of time. This aids in maintaining the necessary blood serum and tissues drug concentrations in the body, preventing any drug-induced harm to healthy tissue. The medication delivery system is extremely interconnected, so it takes experts from several fields—such as chemists, biologists, and engineers—working together to make it as efficient as possible.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia